Detection of human papillomavirus by PCR genotyping and immunostaining in population of Bosnian women
Abstract number: p640
Mahmutovic S., Gravitt P., Hardick A., Beslagic E., Slakovic M., Herawi M., Gaydos C.A.
To determine prevalence of human papilomavirus (HPVs) among Bosnian women.
Cervical swab samples and smears on glass slides were collected from 97 women from three disease defined groups: Group 1: patients who had an abnormal Papanicolaou (PAP) cytology report (N = 34); Group 2: patients who had a history of genitourinary infections (N = 22), Group 3: patients not in either group 1 or 2 (N = 41). Age groups were defined as Group A (2024 yr), Group B (2529 yr), Group C (3034 yr). Group D (3539 yr), Group E (4044 yr), Group F (4549 yr), Group G (>50 yr). Specimens were collected from December 2004 to January 2005 at two sites in Sarajevo: the Department of Gynaecology of the University Medical Center and the Institute for Health Protection of Women and Motherhood. Specimens were shipped to Johns Hopkins University, for testing. Swab samples were tested for high risk (HR) and low risk (LR) types HPV by research Polymerase Chain Reaction PCR (Roche, primer set PGMY 09/11) and for HR HPV by the Hybrid capture-2 (HC2) test (Digene). Slide samples for stained for P-16 protein biomarker (Dako).
The overall prevalence for high risk HPV by HC2 test was 22.68% (22/97). The highest HR-HPV DNA prevalence by HC2 was 31.81% (7/22) in Age Group B. The lowest prevalence was in 4.54% (1/22) in Age Group A. Total of both HR-HPV and LR-HPV prevalence by Roche PCR was 29.89% (29/97). The highest prevalence 34.48% (10/29) was in Age Group B. Positive cytoplasmic immunostaining by p16 biomarker showed prevalence 9.27% (9/31) of total HPV positive patients (HC2 and PCR). By Roche testing the most prevalent HPV genotypes were: HPV 16 (9/29), HPV 52 (4/29), HPV 31, 53, 67 (3/29).
High-risk HPV infection was high among Bosnian women. These results demonstrated that HPV DNA testing was a useful indicator for prevalent of HPV infections and could be adjunct test to PAP testing as a part of regular cervical screening programs among women in Bosnia and Herzegovina in the future.
|Session name:||XXIst ISTH Congress|
|Back to top|